Sleep Apnea Devices Market Revenue to Attain USD 12.39 Bn by 2033

20 Mar 2025

Share :

Table of Content

1. Sleep Apnea Devices Market Revenue and Trends 2023 to 2033 2. Market Overview 3. Report Highlights  4. Market Trends 5. Market News 6. Sleep Apnea Devices Market Companies 7. Market Segmentation

Sleep Apnea Devices Market Revenue and Trends 2023 to 2033

The global sleep apnea devices market revenue reached USD 6.64 billion in 2024 and is predicted to attain around USD 12.39 billion by 2033 with a CAGR of 7%. The global sleep apnea devices market is experiencing significant growth, driven by the increasing prevalence of sleep disorders, rising awareness of sleep-related health issues, and advancements in diagnostic and therapeutic technologies.

Market Overview

The sleep apnea devices market encompasses diagnostic and therapeutic solutions designed to manage sleep-disordered breathing effectively. Two diagnostic categories include polysomnography (PSG) systems and home sleep apnea tests (HSATs). The therapeutic devices are made up of continuous positive airway pressure (CPAP) machines alongside bilevel positive airway pressure (BiPAP) systems and auto-adjusting positive airway pressure (APAP) systems. Patient adherence and treatment results improve through recent advancements in artificial intelligence (AI) linked with cloud-based monitoring platforms. Developing innovations demonstrate how advanced technologies are being integrated into sleep apnea management, as they enhance both early diagnosis capabilities and personalized treatment approaches while improving patient health results.

• In September 2024, the U.S. Food and Drug Administration (FDA) authorized Apple's sleep apnea detection functionality for the Watch Series 9 and Watch Ultra 2 to enter the market. Zepbound (tirzepatide) became the first medication for obstructive sleep apnea treatment in adults with obesity after earning FDA approval in 2024. This approval expanded available options beyond traditional device-based treatment methods. 

Report Highlights 

• By product, the therapeutic devices segment accounted for the largest sleep apnea devices market share due to the rising adoption of CPAP and BiPAP devices in sleep apnea management. This dominance is attributed to the rising adoption of these devices, driven by their proven efficacy in treating sleep-disordered breathing.
• By end user, the hospital settings segment is expected to witness significant growth, driven by the shift toward at-home diagnosis and treatment convenience. This trend is supported by the integration of telehealth solutions, enabling real-time patient monitoring and data-driven therapy adjustments, thereby enhancing treatment accessibility and outcomes. The expansion of telemedicine and remote patient monitoring is improving accessibility to care and enhancing treatment outcomes.

Market Trends

• Growing Awareness and Diagnosis Rates

The rising popularity of public health initiatives with sleep health awareness campaigns helps people understand sleep apnea effects along with its prolonged medical implications. The American Academy of Sleep Medicine (AASM) supports better screening and prompt diagnosis of patients. According to the AASM, obstructive sleep apnea (OSA) means at least five interruptions in breathing or reduced breathing episodes per hour that result in excessive daytime fatigue or present with at least 15 documented hypopnea-apnea events regardless of reported symptoms. The importance of detecting sleep apnea at an early stage becomes evident through recent developments, as does the requirement of complete management strategies for its treatment. 

• Medicare initiative during 2024 brought Eli Lilly's Zepbound (tirzepatide) under coverage for obstructive sleep apnea treatment among adults who have obesity, thereby improving the availability of this therapeutic choice. 
• Research published in Sleep Medicine in 2025 discovered that people who eat cheese present with a 28% decreased risk of developing sleep apnea than those who abstain from dairy products.
• Technological Advancements in Therapeutic Devices

The modern manufacturing industry produces smart continuous positive airway pressure (CPAP) machines with artificial intelligence (AI)-based algorithms that automatically regulate pressure levels by monitoring user breathing patterns in real time. Recent technological developments result in improved comfort as well as better therapy follow-up for patients. Through its cMAP software, NovaResp utilizes AI to supply adjusted air pressures at lower levels which results in better adherence on conventional CPAP devices in 2024. These advanced smart CPAP machines enable healthcare providers to monitor patient data through remote cloud-based systems and make necessary setting changes to customize optimal therapy plans. Sleep apnea treatment has seen a major advancement through these developments, which now creates customized therapy options that cause less disruption to patients.

• Rising Demand for Home Sleep Apnea Testing (HSAT)

The growing preference for at-home diagnosis is driving the adoption of HSATs, which offer a convenient and cost-effective alternative to in-lab sleep studies. Regulatory approvals and insurance coverage expansions are further supporting this trend. Patients perform sleep evaluations through HSATs from their home settings, as they no longer need to undergo tests at medical facilities. Home sleep apnea tests receive insurance coverage from multiple health plans since insurers recognize their combination of effectiveness and affordability. Modern sleep medicine shows a progressive shift toward making advanced healthcare accessible to patients within their homes. 

• Expansion of Telemedicine and Remote Patient Monitoring

The integration of telehealth solutions in sleep apnea management is enabling real-time patient monitoring, remote consultations, and data-driven therapy adjustments. These advancements improve accessibility to care and enhance treatment outcomes. The new developments offer better patient access to healthcare services and lead to superior medical results. The invention of smart pajamas with fabric sensors enables at-home tracking of sleep disorders by wirelessly transferring data to smartphones through their fabric-based sensors. Telehomecare services under telehealth enable the treatment of sleep apnea through patient education while offering support to manage chronic conditions more effectively as healthcare visits become less necessary. Technology development leads to better sleep apnea treatment that provides personalized and efficient care.

Regional Anaylsis

North America dominated the sleep apnea devices market in 2024 and is expected to maintain its leading position supported by high awareness levels, the presence of key market players, and favorable reimbursement policies for sleep disorder treatments. Eli Lilly received U.S. Food and Drug Administration (FDA) authorization for Zepbound (tirzepatide) as the initial medicine for obstructive sleep apnea (OSA) treatment for adults with obesity in December of 2024. CardiacSense gained FDA clearance in 2023 for its CSF-3 wearable watch to track vital signs continuously, including heart rate and oxygen saturation, which improves sleep disorder early identification and management. Furthermore, the strong healthcare infrastructure in North America and emerging medical technology place this region in the lead competitors for sleep apnea solutions.

Asia Pacific is projected to experience the fastest growth in the sleep apnea devices market, supported by rising healthcare investments, growing urbanization, and an increasing burden of undiagnosed sleep apnea cases. Countries like China, India, and Japan are expanding their diagnostic and therapeutic infrastructure to address the growing demand. The rise in Japan's senior citizen population leads to more sleep disorders, which require advanced sleep apnea management technology investments. The sleep apnea devices market in the region exhibits promising development potential because of these emerging trends.

Governments throughout Asia Pacific establish public awareness initiatives and enhance medical coverage to increase access to diagnosis and treatment services for residents. The National Health Commission in China focuses on early identification and treatment of sleep troubles by expanding its primary healthcare system. Through its health insurance policy, Ayushman Bharat promotes affordable access to sleep apnea diagnosis and treatment in India. The initiatives quicken sleep apnea device adoption and reduce the difference between numerous disease cases and scarce medical diagnoses.

Market News

• In January 2025, ResMed launched the AirSense 11 in India, a next-generation Continuous Positive Airway Pressure (CPAP) device aimed at helping individuals with Obstructive Sleep Apnea (OSA) start and maintain therapy.
• In December 2024, the U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for treating moderate to severe OSA in adults with obesity, alongside a reduced-calorie diet and increased physical activity. Zepbound activates hormones that reduce appetite and food intake, helping lower body weight and potentially improving OSA.
• In December 2024, Eli Lilly and Company announced that Zepbound received FDA approval as the first prescription medication specifically for adults with both moderate to severe OSA and obesity, emphasizing its use with diet and exercise.

Sleep Apnea Devices Market Companies

• GE Healthcare
• BMC Medical
• Philips Healthcare
• Weinmann Medical Devices
• CadwellLaboratorie
• Compumedics
• Curative Medical
• Teleflex
• CareFusion Corporation
• Fisher &Paykel Healthcare
• ResMed
• SOMNOmedics
• Invacare Corporation
• Natus Medical

Market Segmentation

By Product Type

• Diagnostic Devices
• Respiratory Polygraphs
• Actigraphs
• Polysomnography (PSG) Device
• Pulse Oximeters
• Therapeutic Devices
• Nasal Devices
• Positive Airway Pressure (PAP) Devices
• Oral Devices
• Chin Straps

By End-User

• Home Care Setting
• Sleep Laborato